| Autor: |
Elinoff JM; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Mazer AJ; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Cai R; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Lu M; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Graninger G; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Harper B; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Ferreyra GA; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Sun J; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland., Solomon MA; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland.; Cardiovascular Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland., Danner RL; Critical Care Medicine Department, Clinical Center, and National Institutes of Health, Bethesda, Maryland. |
| Abstrakt: |
Inflammatory cell infiltrates are a prominent feature of aberrant vascular remodeling in pulmonary arterial hypertension (PAH), suggesting that immune effector cells contribute to disease progression. Genome-wide blood expression profiling studies have attempted to better define this inflammatory component of PAH pathobiology but have been hampered by small sample sizes, methodological differences, and very little gene-level reproducibility. The current meta-analysis (seven studies; 156 PAH patients/110 healthy controls) was performed to assess the comparability of data across studies and to possibly derive a generalizable transcriptomic signature. Idiopathic (IPAH) compared with disease-associated PAH (APAH) displayed highly similar expression profiles with no differentially expressed genes, even after substantially relaxing selection stringency. In contrast, using a false discovery rate of ≤1% and I 2 < 40% (low-to-moderate heterogeneity across studies) both IPAH and APAH differed markedly from healthy controls with the combined PAH cohort yielding 1,269 differentially expressed, unique gene transcripts. Bioinformatic analyses, including gene-set enrichment, which uses all available data independent of gene selection thresholds, identified interferon, mammalian target of rapamycin/p70S6K, stress kinase, and Toll-like receptor signaling as enriched mechanisms within the PAH gene signature. Enriched biological functions and diseases included tumorigenesis, autoimmunity, antiviral response, and cell death consistent with prevailing theories of PAH pathogenesis. Although otherwise indistinguishable, APAH (predominantly PAH due to systemic sclerosis) had a somewhat stronger interferon profile than IPAH. Meta-analysis defined a robust and generalizable transcriptomic signature in the blood of PAH patients that can help inform the identification of biomarkers and therapeutic targets. |
